Equities

Medinet Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2370:TYO

Medinet Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)31.00
  • Today's Change1.00 / 3.33%
  • Shares traded76.60k
  • 1 Year change-13.89%
  • Beta0.7270
Data delayed at least 15 minutes, as of Feb 18 2026 00:47 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

MEDINET Co., Ltd. is a Japan-based company mainly engaged in cell processing industry and cellular medical products business. It operates through two business segments. The Cell Processing Industry segment mainly engages in comprehensive support services for immune cell therapy, related services including clinical use from companies, universities, research institutes, outsourcing of cell processing for clinical trials and operation of cell culture processing facilities. The Cellular Medical Products segment is mainly engaged in research and development for obtaining approval for manufacture and marketing of cellular medical products. It also provides comprehensive support services for immune cell therapy.

  • Revenue in JPY (TTM)787.09m
  • Net income in JPY-1.36bn
  • Incorporated1995
  • Employees107.00
  • Location
    Medinet Co Ltd9F, TRC Center Bldg., 6-1-1, HeiwajimaOTA-KU 143-0006JapanJPN
  • Phone+81 366311201
  • Fax+81 366311202
  • Websitehttps://www.medinet-inc.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Modalis Therapeutics Corp0.00-2.15bn5.16bn14.00--1.83-----28.13-28.130.0032.230.00-------64.69-47.62-67.23-49.48-------22,365.60-------------63.34---68.51--
D.Western Therapeutics Institute Inc387.62m-632.09m5.48bn21.00--3.82--14.14-13.31-13.318.0926.460.20190.41153.53---32.93-28.15-36.09-30.6889.9792.09-163.07-155.999.48--0.2966---17.801.7451.01---11.74--
TMS Co Ltd0.00-670.20m6.23bn18.00--2.08-----15.72-15.720.0065.780.00----0.00-21.59---22.41----------23.99--0.00------31.20------
Carna Biosciences, Inc.579.06m-2.17bn6.43bn63.00--20.80--11.11-113.62-113.6230.3016.160.28941.246.17---108.53-37.21-120.28-41.9867.0386.49-375.00-118.286.08-75.550.6979---8.99-12.570.3262---33.02--
Noile-Immune Biotech Inc7.14m-782.47m6.67bn25.00--1.62--933.57-18.07-18.070.16595.160.00160.000.0668285,720.00-17.08---17.32--30.00---10,954.38--60.62--0.00---97.61--14.65------
Cyfuse Biomedical KK-100.00bn-100.00bn6.75bn21.00--2.36----------286.90-----------13.87---16.49--68.61---178.864.44--0.3224--324.2710.9412.43--182.58--
Tsubota Laboratory Inc710.56m-398.77m6.86bn17.00--6.21--9.66-15.53-15.5327.5542.860.35940.452250.4641,797,700.00-20.170.1041-29.560.151781.6571.43-56.120.22162.60--0.06340.00101.4925.17132.08132.7026.42--
Chiome Bioscience Inc593.29m-982.78m7.64bn47.00--6.71--12.88-14.48-14.488.7416.390.28284.979.64---46.84-52.22-59.06-64.4159.9357.59-165.65-174.883.99-1,177.610.1891---24.024.293.72------
Linical Co Ltd9.32bn-1.77bn7.74bn598.00--1.25--0.8309-78.51-78.51412.61251.020.5937--3.6215,584,280.00-11.302.59-20.504.1917.4829.24-19.033.74---192.930.293377.26-15.20-0.9283-259.37---42.014.24
OncoTherapy Science, Inc.784.25m-881.65m7.91bn47.00--3.70--10.09-2.93-2.932.605.680.42248.388.7216,686,090.00-47.48-63.66-56.22-77.433.63-0.3852-112.42-184.758.13-832.790.0043--22.9318.8636.71---70.80--
PRISM BioLab Co Ltd677.33m-833.70m7.98bn35.00--2.94--11.78-22.84-22.8418.5473.590.1779--12.5819,352,290.00-21.90---26.79--39.83---123.09------0.00--121.62--20.56------
Medinet Co Ltd787.09m-1.36bn8.27bn107.00--2.39--10.50-5.12-5.122.9712.950.170111.083.007,355,991.00-29.29-22.42-31.04-23.6413.5817.68-172.25-173.5911.33--0.00--5.440.6867-6.67--10.06--
Chordia Therapeutics Inc0.00-1.46bn8.68bn20.00--3.64-----21.23-21.230.0032.670.00----0.00-46.77---49.97-------------222.950.00------2.26------
BrightPath Biotherapeutics Co Ltd1.11m-1.08bn8.70bn24.00--4.82--7,834.82-11.59-11.590.011713.700.0007----46,250.00-63.35-59.65-74.36-63.7897.6673.74-96,860.36-28,727.67---1,103.910.00--1,473.61-36.871.45---58.41--
Nano Holdings Inc156.34m-887.50m11.68bn20.00--4.23--74.69-12.46-12.462.1936.190.030844.495.297,817,050.00-17.51-23.68-22.01-25.3789.5482.69-567.67-746.835.93--0.4829---19.92-27.80-7.10------
Data as of Feb 18 2026. Currency figures normalised to Medinet Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

0.24%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 05 Feb 2026632.50k0.24%
Data from 05 Feb 2026 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.